4D Molecular Therapeutics (4DMT) has said a trial of its gene therapy for Fabry disease has been placed on a clinical hold by the FDA, a few weeks after it reported three cases of atypical ...

A "productive" meeting with the FDA has given the firm confidence in its regulatory filing and commercialization plans for ST-920.

The company said that recently announced partnerships with Roche's Genentech unit and Astellas, and advanced business development discussions for its Fabry gene therapy programme (isaralgagene ...

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $162 million, has reached a significant milestone in the development of its gene therapy product ...

its wholly owned gene therapy product candidate for the treatment of Fabry disease. All dosed patients in the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec have now completed at least ...

Glycosyrin represents a novel type of "iminosugars," many of which are used as human drugs to treat metabolic disorders such as type-II diabetes and Fabry disease, because they are stable and ...

has reached a significant milestone in the development of its gene therapy product candidate for Fabry disease, isaralgagene civaparvovec, also known as ST-920. According to InvestingPro data ...